Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Dreamy Small-Cap Stocks
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Hedge Your Portfolio with the Equity Bear ETF
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Luminex Corp develops and manufactures proprietary biological testing technologies and products for the life sciences industry. The company has a market cap of $886 million.
Third-Quarter Results
Shares of LMNX have been rallying since the company reported strong third-quarter results on Nov 7. Revenue jumped to $29 million from $19.3 million last year. Income increased to $3.2 million from a loss of $1.9 million. This produced earnings of 8 cents per share, far ahead of analyst estimates of 1 cent.
Luminex said that its results benefited from partnerships with Genzyme Corp. and Becton, Dickinson and Co. in developing diagnostic tests. The results also included a $1.8 million stock compensation charge and a $600,000 hit related to the amortization of intangible assets.
Internationl Growth
On Nov 20, Luminx announced that it had reached an agreement with Mingyuan Medicare Development Co, a Chinese-based medical products distributor, to serve as the exclusive distributor of its products in both China and Hong Kong. Luminex noted that 20 million babies are born in China every and that the Chinese government mandates testing in order to detect genetic disorders.
Guidance and Estimates
After the solid performance, Luminex went ahead and boosted its full-year revenue guidance to between $102 million and $107 million, up from the previous $95 million to $105 million.
The analyst community is bullish on the company as well, with the next-year estimate pegged at 32 cents per share, a whopping 359% earnings growth projection.
The Chart
As previously mentioned, shares of LMNX have been rallying since news of the good quarter hit the street, jumping from $12.50 to a recent high above $22. The next-year estimate is bullish, but this is an expensive stock, so Luminex will need to deliver more impressive growth in order to drive shares higher. Take a look at the chart below.
Read the full reports :
Analyst Report on LMNX